Skip to main content

Table 1 Baseline characteristics of included trials

From: Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials

Study Disease No. of patients Type of devices DAPT(mts) MACE Follow-up (mts) Pre- dilatation (n/lesions)
    DEB(+BMS) DES     DEB DES
Adriaenssens 2014 [30] SEDUCE BMS-ISR 50 PEB(SeQuent Please) EES(XIENCE V/Prime) NA NA 9 (angio), 12 (clinical) 25/25 25/25
Alfonso 2015 [31] RIBS IV DES-ISR 309 PEB(SeQuent Please) EES(XIENCE Prime) 3 after DEB, 12 after DES NA 6–9 angio), 12–36 (clinical) 154/154 155/155
Alfonso 2014 [32] RIBS V BMS-ISR 189 PEB(SeQuent Please) EES(XIENCE Prime) 3 after DEB, 12 after DES NA 6–9 (angio), 12 (clinical) 95/95 94/94
Ali 2011 [39] PEPCAD IV coronary stenoses in patients with DM 84 DEB(SeQuent Please) + cobalt-chromium stent(Coroflex Blue) DES (Taxus Liberté) 3 after DEB, 6 after DES NA 9 14/45 38/39
Belkacemi 2012 [23] DEB-AMI AMI 99 DIOR 2 DEB + cobalt-chromium stent DES (Taxus Liberté) 12 MI, TVR, death 6 30/50 49/49
Byrne 2013 [33] ISAR-DESIRE 3 DES-ISR 268 DEB(SeQuent Please) DES (Taxus Liberté) 6 Death, MI, TLR 6–8 (angio), 12–36 (clinical) 139/172 145/168
Chae 2017 [24] De novo lesions 180 DEB(Sequent® Please) + BMS(Coroflex® Blue) ZES(Resolute Integrity) 9 TLR, MI, cardiac death 12 74/74 72/72
Clever 2014 [25] De novo lesions 52 DEB(Braun) + BMS(Coroflex Blue) SES(Cypher) 9 TLR, MI, ST, death 9 16/27 16/25
Cortese 2010 [37] PICCOLETO small coronary vessels 60 DIOR 1 DEB DES (Taxus Liberté) 1 after DEB, 3 after BMS, 12 after DES Death, STEMI, TLR 6 (angio), 9(clinical) 7/28 25/29
Herdeg 2009 [26] De novo stenoses 136 BMS (Multi-Link Zeta, Guidant)followed by catheter-based local delivery of fluid paclitaxel DES (Taxus Liberté) 6 TLR, MI, subacute closure, or death 6 NA NA
Latib 2012 [38] BELLO Small Coronary Vessels 182 IN.PACT Falcon DEB DES (Taxus Liberté) 1 after DEB, 12 after DES Death, MI,TVR 6 (angio), 6–36 (clinical) 91/94 81/98
Liistro 2013 [27] de novo coronary stenosis 125 Elutax PEB + cobalt-chromium EES(XIENCE Prime) 3 after DEB, 12 after DES MI, death, TLR 9 NA NA
Minguez 2014 [41] BABILON de novo bifurcated coronary lesions 108 DEB(SeQuent Please) + cobalt-Chromium stent(Coroflex Blue) EES(XIENCE Prime) 3 after DEB, 12 after DES Death, MI, TLR 9(angio), 24 (clinical) 43/43 43/43
Pleva 2016 [34] BMS-ISR 136 PEB(SeQuent Please) EES(Promus Element) 3 after DEB, 6–12 after DES MI, TVR, Cardiac death 12 69/69 68/68
Poerner 2014 [28] coronary artery disease 90 DEB(SeQuent Please) + cobalt-chromium stent(Coroflex Blue) EES(XIENCE Prime) NA NA 6 NA NA
Stella 2012 [40] coronary bifurcation lesions 80 Dior I DEB + Liberte BMS DES (Taxus Liberté) 3 after DEB, 12 after DES MI, TVR, Death 12 33/33 37/37
Unverdorben 2009 [35] PEPCAD II ISR 131 PEB(SeQuent Please) DES (Taxus Liberté) 3 after DEB, 6 after DES MI, TLR, Cardiac Death, Stent thrombosis 6 (angio), 12–36 (clinical) 66/66 65/65
Xu 2014 [36] PEPCAD China ISR DES-ISR 215 PEB(SeQuent Please) DES (Taxus Liberté) 12 MI, TLR, Cardiac death 9 (angio), 12 (clinical) 112/113 107/108
Zurakowski 2015 [29] de novo coronary lesions 202 DEB(Sequent Please) + BMS DES(Coroflex Please) 12 MI, TVR, Cardiac death 9 NA NA